• +1-646-491-9876
    • +91-20-67278686

    Search

    Tyrosine Protein Kinase JAK1-Pipeline Review H1 2017

    Tyrosine Protein Kinase JAK1-Pipeline Review H1 2017

    • Report Code ID: RW0001834369
    • Category Pharmaceuticals
    • No. of Pages 134
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017

    Summary

    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 4, 11 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology which include indications Rheumatoid Arthritis, Ulcerative Colitis, Atopic Dermatitis, Alopecia, Psoriasis, Chronic Lymphocytic Leukemia (CLL) , Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Ankylosing Spondylitis (Bekhterev's Disease) , B-Cell Non-Hodgkin Lymphoma, Crohn's Disease (Regional Enteritis) , Graft Versus Host Disease (GVHD) , Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Mantle Cell Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL) , Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma (ALCL) , Asthma, Auto Inflammatory Disease, Autoimmune Disorders, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Endometrial Cancer, Eosinophilia, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Giant Cell Arteritis, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease) , Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris) , Post-Polycythemia Vera Myelofibrosis (PPV-MF) , Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL) , Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Respiratory Tract Inflammatory Disorders, Sicca Syndrome (Sjogren) , Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) , Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma) .

    Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
    - The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 6
    List of Figures 6
    Introduction 8
    Publisher Report Coverage 8
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview 9
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development 10
    Products under Development by Stage of Development 10
    Products under Development by Therapy Area 11
    Products under Development by Indication 12
    Products under Development by Companies 17
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment 25
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 26
    Assessment by Molecule Type 28
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 29
    AbbVie Inc 29
    Aclaris Therapeutics Inc 29
    Advinus Therapeutics Ltd 30
    Astellas Pharma Inc 31
    AstraZeneca Plc 31
    Chipscreen Biosciences Ltd 32
    CJ HealthCare Corp 32
    Eli Lilly and Company 33
    Galapagos NV 34
    Incyte Corp 34
    Japan Tobacco Inc 37
    Jiangsu Hengrui Medicine Co Ltd 37
    Nissan Chemical Industries Ltd 38
    Pfizer Inc 38
    Portola Pharmaceuticals Inc 39
    Sareum Holdings Plc 40
    Theravance Biopharma Inc 41
    Vectura Group Plc 41
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles 42
    ABBV-599 - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    ATI-50001 - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    ATI-50002 - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    AZD-0449 - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    AZD-1480 - Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    AZD-4205 - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    baricitinib - Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    cerdulatinib - Drug Profile 59
    Product Description 59
    Mechanism Of Action 59
    R&D Progress 59
    CS-944X - Drug Profile 63
    Product Description 63
    Mechanism Of Action 63
    R&D Progress 63
    filgotinib - Drug Profile 64
    Product Description 64
    Mechanism Of Action 64
    R&D Progress 64
    INCB-52793 - Drug Profile 76
    Product Description 76
    Mechanism Of Action 76
    R&D Progress 76
    itacitinib adipate - Drug Profile 77
    Product Description 77
    Mechanism Of Action 77
    R&D Progress 77
    JTE-052 - Drug Profile 81
    Product Description 81
    Mechanism Of Action 81
    R&D Progress 81
    NIP-565 - Drug Profile 82
    Product Description 82
    Mechanism Of Action 82
    R&D Progress 82
    peficitinib hydrobromide - Drug Profile 83
    Product Description 83
    Mechanism Of Action 83
    R&D Progress 83
    PF-04965842 - Drug Profile 86
    Product Description 86
    Mechanism Of Action 86
    R&D Progress 86
    PF-06700841 - Drug Profile 87
    Product Description 87
    Mechanism Of Action 87
    R&D Progress 87
    PNQ-401 - Drug Profile 89
    Product Description 89
    Mechanism Of Action 89
    R&D Progress 89
    PNQ-701 - Drug Profile 90
    Product Description 90
    Mechanism Of Action 90
    R&D Progress 90
    ruxolitinib phosphate - Drug Profile 91
    Product Description 91
    Mechanism Of Action 91
    R&D Progress 91
    SAR-20347 - Drug Profile 106
    Product Description 106
    Mechanism Of Action 106
    R&D Progress 106
    SART-29 - Drug Profile 108
    Product Description 108
    Mechanism Of Action 108
    R&D Progress 108
    SHR-0302 - Drug Profile 109
    Product Description 109
    Mechanism Of Action 109
    R&D Progress 109
    Small Molecules to Inhibit Jak1 for Oncology - Drug Profile 110
    Product Description 110
    Mechanism Of Action 110
    R&D Progress 110
    Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis - Drug Profile 111
    Product Description 111
    Mechanism Of Action 111
    R&D Progress 111
    TD-1473 - Drug Profile 112
    Product Description 112
    Mechanism Of Action 112
    R&D Progress 112
    TD-3504 - Drug Profile 114
    Product Description 114
    Mechanism Of Action 114
    R&D Progress 114
    upadacitinib tartrate - Drug Profile 115
    Product Description 115
    Mechanism Of Action 115
    R&D Progress 115
    VR-588 - Drug Profile 119
    Product Description 119
    Mechanism Of Action 119
    R&D Progress 119
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products 120
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products 121
    Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones 123
    Featured News & Press Releases 123
    May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 123
    May 15, 2017: Seven abstracts on filgotinib accepted by EULAR 2017 123
    May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 124
    May 09, 2017: AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494) , an Investigational JAK1-Selective Inhibitor, in Crohn's Disease 124
    May 07, 2017: Galapagos presents three posters on filgotinib in Crohn's disease at DDW 2017 125
    May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 126
    Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 127
    Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib 127
    Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 128
    Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders 128
    Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 129
    Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease 129
    Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 130
    Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 131
    Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis 132
    Appendix 133
    Methodology 133
    Coverage 133
    Secondary Research 133
    Primary Research 133
    Expert Panel Validation 133
    Contact Us 133
    Disclaimer 134

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017 10
    Number of Products under Development by Therapy Areas, H1 2017 11
    Number of Products under Development by Indications, H1 2017 12
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 14
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 15
    Number of Products under Development by Indications, H1 2017 (Contd..3) , H1 2017 16
    Number of Products under Development by Companies, H1 2017 17
    Products under Development by Companies, H1 2017 18
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 19
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 20
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 21
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 22
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 23
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 24
    Number of Products by Stage and Mechanism of Actions, H1 2017 25
    Number of Products by Stage and Route of Administration, H1 2017 27
    Number of Products by Stage and Molecule Type, H1 2017 28
    Pipeline by AbbVie Inc, H1 2017 29
    Pipeline by Aclaris Therapeutics Inc, H1 2017 30
    Pipeline by Advinus Therapeutics Ltd, H1 2017 30
    Pipeline by Astellas Pharma Inc, H1 2017 31
    Pipeline by AstraZeneca Plc, H1 2017 31
    Pipeline by Chipscreen Biosciences Ltd, H1 2017 32
    Pipeline by CJ HealthCare Corp, H1 2017 32
    Pipeline by Eli Lilly and Company, H1 2017 33
    Pipeline by Galapagos NV, H1 2017 34
    Pipeline by Incyte Corp, H1 2017 35
    Pipeline by Japan Tobacco Inc, H1 2017 37
    Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 37
    Pipeline by Nissan Chemical Industries Ltd, H1 2017 38
    Pipeline by Pfizer Inc, H1 2017 38
    Pipeline by Portola Pharmaceuticals Inc, H1 2017 39
    Pipeline by Sareum Holdings Plc, H1 2017 40
    Pipeline by Theravance Biopharma Inc, H1 2017 41
    Pipeline by Vectura Group Plc, H1 2017 41
    Dormant Projects, H1 2017 120
    Discontinued Products, H1 2017 121
    Discontinued Products, H1 2017 (Contd..1) , H1 2017 122

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017 10
    Number of Products under Development by Therapy Areas, H1 2017 11
    Number of Products under Development by Top 10 Indications, H1 2017 12
    Number of Products by Stage and Mechanism of Actions, H1 2017 25
    Number of Products by Routes of Administration, H1 2017 26
    Number of Products by Stage and Routes of Administration, H1 2017 26
    Number of Products by Stage and Molecule Type, H1 2017 28
    AbbVie Inc
    Aclaris Therapeutics Inc
    Advinus Therapeutics Ltd
    Astellas Pharma Inc
    AstraZeneca Plc
    Chipscreen Biosciences Ltd
    CJ HealthCare Corp
    Eli Lilly and Company
    Galapagos NV
    Incyte Corp
    Japan Tobacco Inc
    Jiangsu Hengrui Medicine Co Ltd
    Nissan Chemical Industries Ltd
    Pfizer Inc
    Portola Pharmaceuticals Inc
    Sareum Holdings Plc
    Theravance Biopharma Inc
    Vectura Group Plc

    Request for Sample

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-jak1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-jak1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-jak1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments